Skip to content
Popular Searches
  • # Cancer
  • # FDA
  • # Alzheimer's
  • # DNA
  • # Diabetes
  • # Hoffmann-La Roche
  • linkedin
  • facebook
  • instagram
  • twitter
  • youtube
Home BiotechReality – Covering Industry, Business, and Academia

Explore the frontiers of Biotechnology, Pharma/Biopharma industry and Science with BiotechReality. We publish news, reports, views and articles.

  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
Trending

Trending

Antibiotics: Mode of Action and Types

30 September 2023

Effective Drug Development Using Fewer Mice

19 March 2025

SARS-CoV-2 which causes COVID-19 is widespread in wild animals

31 July 2024

GSK Released EMBRACE a Phase 2b Clinical Trial Data of an Investigational Broadly Neutralising Antibody for HIV

18 March 2025

A new way, that could lead to universal, long-lasting flu shot

10 May 2024

HPLC – High-Performance Liquid Chromatography

2 September 2023

New antibody therapy to neutralize a wide variety of HIV-1 strains

19 July 2024

U.S. FDA Approved Amgen’s UPLIZNA® (INEBILIZUMAB-CDON) for the Treatment of Rare Immune Disorder

6 April 2025

A Novel Method for Forecasting Drug Resistance in Malaria

11 December 2024

Dupixent (Dupilumab), Sanofi’s New Targeted Therapy For Chronic Spontaneous Urticaria Approved by the U.S. FDA

19 April 2025

GelDoc: A Revolutionary Tool for DNA and Protein Analysis

30 May 2023

Environmental Bacteria Could Form Better Antibiotics

16 August 2024

Dupilumab

Dupixent (Dupilumab), Sanofi’s New Targeted Therapy For Chronic Spontaneous Urticaria Approved by the U.S. FDA
Healthcare & Pharmaceuticals News Regulatory Approval

Dupixent (Dupilumab), Sanofi’s New Targeted Therapy For Chronic Spontaneous Urticaria Approved by the U.S. FDA

Ajmal Aseem 19 April 2025

Phase 3 tests showing Dupixent dramatically decreased itching and hives when compared to a placebo led to approval.

Areas Covered

  • Anti-obesity Drugs
  • Applications of Biotechnology
  • Artificial Intelligence
  • Astrobiology
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • Cell Biology
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Life Sciences
  • Machine Learning
  • Medical Devices
  • Mental Health
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Pharmacology
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Staining
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs
Market Analysis
Publish on BiotechReality

  • Sartorius is Hiring a Process Technology Engineer in Bengaluru, India – May, 2025
  • Cytiva Hiring a Logistics Specialist in Singapore – May 2025
  • AstraZeneca is Hiring an AI Engineer – Lead Consultant in Chennai, India – May 2025
  • Schrödinger is Hiring a Quality Assurance Associate – Hyderabad, India – May 2025
  • Roche Hiring Veeva Vault Business Systems Analysis Expert – Pune, India
SciRealityPress BiotechReality

A SciRealityPress Associate

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2025
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinuePrivacy policy